Liberty Global Ltd Class C vs uniQure N.V. Ordinary Shares — how do they compare? Liberty Global Ltd Class C trades at $8.03 (market cap $2.94B), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: Liberty Global Ltd Class C is the larger of the two by market cap, and uniQure N.V. Ordinary Shares is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Global Ltd Class C for 20 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| LBTYK | QURE | |
|---|---|---|
Market Cap | $2.94B | $1.48B |
Volume | 1,441,876 | 2,488,780 |
Sector | Media | Health |
52-Week High | $12.67 | $70.59 |
52-Week Low | $8.03 | $9.03 |
Typical Hold Time | 20 Days | 0 Days |
Enterprise Value | $9.60B | $728.62M |
Signals from Pluang's Aura AI — not financial advice
Liberty Global (LBTYK) trades at $8.41, showing minimal daily movement with a 0.24% gain. The stock faces bearish technical signals but maintains strong analyst support with 69% buy ratings and a $12.67 consensus target. Recent financials show mixed performance with negative net income margins (-62.14%) despite solid gross margins (67.17%), while strategic moves like the Ziggo Group spin-off and AI partnerships aim to unlock value by 2027.
The outlook remains cautiously optimistic given the significant upside to analyst targets and ongoing corporate restructuring. Key risks include persistent profitability challenges and execution risks around the Ziggo listing. The stock's deep value proposition (P/S 0.59, P/B 0.31) offers potential for patient investors despite near-term volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →